Wanda Destiarani

Ms. Wanda Destiarani

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Ari HardiantoAri Hardianto
Ari Hardianto
SMSarah Syifa Mardetia
Sarah Syifa Mardetia
WDWanda Destiarani
Wanda Destiarani
YBYudha Prawira Budiman
Yudha Prawira Budiman
DKDikdik Kurnia
Dikdik Kurnia
TMTri Mayanti
Tri Mayanti
Breast cancer is a significant global concern, with tamoxifen, the standard treatment, raising long-term safety issues due to side effects. In this study, we evaluated the potential of five onoceranoid triterpenes from Lansium domesticum Corr. cv. kokosan against estrogen receptor alpha (ERα) using in silico techniques. Utilizing molecular docking, Lipinski’s rule of five, in silico ADMET, and molecular dynamics simulations, we assessed the potency of five onoceranoid triterpenes against ERα. Molecular docking indicated competitive binding energies for these triterpenes relative to the active form of tamoxifen (4OHT) and estradiol, an ERα native ligand. Three triterpenes met drug-likeness criteria with favorable ADMET profiles. Notably, 2 demonstrated superior binding affinity in molecular dynamics simulations, outperforming estradiol, closely followed by 3 and 4. Hierarchical clustering on principal components (HCPC) and the spatial distribution of contact surface area (CSA) analyses suggest that these triterpenes, especially 2, may act as antagonist ligands akin to 4OHT. These findings highlight the potential of onoceranoid triterpenes in treating ERα-related breast cancer.

Verified
Journal Article
Open access
PDF file
MYMuhammad Yusuf
Muhammad Yusuf
WDWanda Destiarani
Wanda Destiarani
AFAde Rizqi Ridwan Firdaus
Ade Rizqi Ridwan Firdaus
Fauzian Giansyah Giansyah rohmatullohFauzian Giansyah Giansyah rohmatulloh
Fauzian Giansyah Giansyah rohmatulloh
MNMia Tria Novianti
Mia Tria Novianti
RDReiva Farah Dwiyana
Reiva Farah Dwiyana
LL-37 is a membrane-active antimicrobial peptide (AMP) that could disrupt the integrity of bacterial membranes due to its inherent cationic and amphipathic nature. Developing a shorter derivative of a long peptide such as LL-37 is of great interest, as it can reduce production costs and cytotoxicity. However, more detailed information about the residual interaction between LL-37 and the membrane is required for further optimization. Previously, molecular dynamics simulation using mixed all-atom and united-atom force fields showed that LL-37 could penetrate the bilayer membrane. This study aimed to perform all-atom molecular dynamics simulations, highlighting the residual interaction of LL-37 with the simplest model of the bacterial membrane, POPE:POPG (2:1), and compare its interaction with the POPC, which represents the eukaryotic membrane. The result showed leucine–leucine as the leading residues of LL-37 that first contact the membrane surface. Then, the cationic peptide of LL-37 started to penetrate the membrane by developing salt bridges between positively charged amino acids, Lys–Arg, and the exposed phosphate group of POPE:POPG, which is shielded in POPC. Residues 18 to 29 are suggested as the core region of LL-37, as they actively interact with the POPE:POPG membrane, not POPC. These results could provide a basis for modifying the amino acid sequence of LL-37 and developing a more efficient design for LL-37 derivatives.

4 August 2023 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
RJRegaputra S. Janitra
Regaputra S. Janitra
WDWanda Destiarani
Wanda Destiarani
AHAri Hardianto
Ari Hardianto
UBUmi Baroroh
Umi Baroroh
FRFauzian G. Rohmatulloh
Fauzian G. Rohmatulloh
MYMuhammad Yusuf
Muhammad Yusuf

5 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MYMuhammad Yusuf
Muhammad Yusuf
WDWanda Destiarani
Wanda Destiarani
WWWahyu Widayat
Wahyu Widayat
YYYosua Yosua
Yosua Yosua
GGGilang Gumilar
Gilang Gumilar
TSToto Subroto
Toto Subroto
Epitope-based peptide vaccine can elicit T-cell immunity against SARS-CoV-2 to clear the infection. However, finding the best epitope from the whole antigen is challenging. A peptide screening using immunoinformatics usually starts from MHC-binding peptide, immunogenicity, cross-reactivity with the human proteome, to toxicity analysis. This pipeline classified the peptides into three categories, i.e., strong-, weak-, and non-binder, without incorporating the structural aspect. For this reason, the molecular detail that discriminates the binders from non-binder is interesting to be investigated. In this study, five CTL epitopes against HLA-A*02:01 were identified from the coarse-grained molecular dynamics-guided immunoinformatics screening. The strong binder showed distinctive activities from the non-binder in terms of structural and energetic properties. Furthermore, the second residue from the nonameric peptide was most important in the interaction with HLA-A*02:01. By understanding the nature of MHC-peptide interaction, we hoped to improve the chance of finding the best epitope for a peptide vaccine candidate.

30 April 2026 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
WDWanda Destiarani
Wanda Destiarani
KHKowit Hengphasatporn
Kowit Hengphasatporn
Yasuteru ShigetaYasuteru Shigeta
Yasuteru Shigeta
RHRyuhei Harada
Ryuhei Harada
Therapeutic antibodies face on-target/off-tumor toxicity, causing adverse effects such as cardiotoxicity, skin rashes, and organ inflammation.